Does botulinum toxin have any role in the management of chronic pain associated with bruxism?

IF 2 4区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Cranio-The Journal of Craniomandibular & Sleep Practice Pub Date : 2024-03-01 Epub Date: 2021-07-14 DOI:10.1080/08869634.2021.1949536

Hessa M Alwayli, Baraa Issam Abdulrahman, Sanjay Rastogi

{"title":"Does botulinum toxin have any role in the management of chronic pain associated with bruxism?","authors":"Hessa M Alwayli, Baraa Issam Abdulrahman, Sanjay Rastogi","doi":"10.1080/08869634.2021.1949536","DOIUrl":null,"url":null,"abstract":"Objective: To determine the efficacy of injectable botulinum toxin (BTA) in the management of pain associated with nocturnal bruxism.Methods: The study subjects consisted of 40 male and female volunteers who complained of chronic pain in the masseter muscles bilaterally due to bruxism. Twenty units of BTA were injected bilaterally into the masseter muscles. Clinical parameters of pain at rest and chewing were assessed at baseline, 2, 4, 8, 12, 16, 18, and 24 weeks using the visual pain scale (VPS).Results: The study included 24 females and 16 males aged 21 to 52 years (mean 33.9 ± 31.0). The mean VPS score on the first day was 5.75 (SD 1.9), significantly decreasing after two weeks to 0.44 (SD 0.727). The mean difference of VPS from 8 weeks up to 24 weeks gradually increase from 0.69 at 8 weeks to 2.00 at 24 weeks.Conclusion: This study provides evidence that BTA could reduce the pain of nocturnal bruxism in affected patients.","PeriodicalId":56318,"journal":{"name":"Cranio-The Journal of Craniomandibular & Sleep Practice","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cranio-The Journal of Craniomandibular & Sleep Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08869634.2021.1949536","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determine the efficacy of injectable botulinum toxin (BTA) in the management of pain associated with nocturnal bruxism.

Methods: The study subjects consisted of 40 male and female volunteers who complained of chronic pain in the masseter muscles bilaterally due to bruxism. Twenty units of BTA were injected bilaterally into the masseter muscles. Clinical parameters of pain at rest and chewing were assessed at baseline, 2, 4, 8, 12, 16, 18, and 24 weeks using the visual pain scale (VPS).

Results: The study included 24 females and 16 males aged 21 to 52 years (mean 33.9 ± 31.0). The mean VPS score on the first day was 5.75 (SD 1.9), significantly decreasing after two weeks to 0.44 (SD 0.727). The mean difference of VPS from 8 weeks up to 24 weeks gradually increase from 0.69 at 8 weeks to 2.00 at 24 weeks.

Conclusion: This study provides evidence that BTA could reduce the pain of nocturnal bruxism in affected patients.

查看原文本刊更多论文

肉毒杆菌毒素在治疗与磨牙症相关的慢性疼痛方面有什么作用吗？

目的：确定注射肉毒杆菌毒素（BTA）治疗夜间磨牙症相关疼痛的疗效：确定注射肉毒杆菌毒素（BTA）治疗夜间磨牙症相关疼痛的疗效：研究对象包括 40 名男性和女性志愿者，他们主诉因磨牙症导致双侧颌下肌肉慢性疼痛。向双侧咀嚼肌注射 20 个单位的 BTA。在基线、2、4、8、12、16、18 和 24 周时使用视觉疼痛量表（VPS）评估休息和咀嚼时疼痛的临床参数：研究对象包括 24 名女性和 16 名男性，年龄在 21 至 52 岁之间（平均 33.9 ± 31.0）。第一天的平均 VPS 评分为 5.75（标准差 1.9），两周后明显降低至 0.44（标准差 0.727）。从 8 周到 24 周，VPS 的平均差异从 8 周的 0.69 逐渐增加到 24 周的 2.00：本研究证明，BTA 可以减轻夜间磨牙症患者的疼痛。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cranio-The Journal of Craniomandibular & Sleep Practice DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

4.50

自引率

12.50%

发文量

审稿时长

>12 weeks

期刊介绍： CRANIO: The Journal of Craniomandibular & Sleep Practice is the oldest and largest journal in the world devoted to temporomandibular disorders, and now also includes articles on all aspects of sleep medicine. The Journal is multidisciplinary in its scope, with editorial board members from all areas of medicine and dentistry, including general dentists, oral surgeons, orthopaedists, radiologists, chiropractors, professors and behavioural scientists, physical therapists, acupuncturists, osteopathic and ear, nose and throat physicians. CRANIO publishes commendable works from outstanding researchers and clinicians in their respective fields. The multidisciplinary format allows individuals practicing with a TMD emphasis to stay abreast of related disciplines, as each issue presents multiple topics from overlapping areas of interest. CRANIO''s current readership (thousands) is comprised primarily of dentists; however, many physicians, physical therapists, chiropractors, osteopathic physicians and other related specialists subscribe and contribute to the Journal.